MediWound (NASDAQ:MDWD) Upgraded to “Sell” by StockNews.com

StockNews.com upgraded shares of MediWound (NASDAQ:MDWD) to a sell rating in a report published on Tuesday morning.

Separately, HC Wainwright reaffirmed a buy rating and set a $28.00 price objective on shares of MediWound in a research note on Friday, March 22nd.

MediWound Stock Down 3.2 %

NASDAQ MDWD opened at $18.61 on Tuesday. The company’s 50 day moving average is $15.68 and its 200-day moving average is $12.21. MediWound has a 12-month low of $7.10 and a 12-month high of $19.80. The firm has a market cap of $176.61 million, a P/E ratio of -24.17 and a beta of 0.93.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.04. The company had revenue of $5.34 million for the quarter, compared to analyst estimates of $5.33 million. MediWound had a negative net margin of 35.94% and a negative return on equity of 20.22%. Equities analysts expect that MediWound will post -1.93 EPS for the current year.

Hedge Funds Weigh In On MediWound

Several hedge funds have recently bought and sold shares of the company. Yelin Lapidot Holdings Management Ltd. grew its stake in MediWound by 45.7% in the 4th quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock worth $1,276,000 after buying an additional 39,348 shares in the last quarter. Sargent Investment Group LLC grew its stake in MediWound by 7.0% in the 4th quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock worth $1,111,000 after buying an additional 7,125 shares in the last quarter. Finally, Silverberg Bernstein Capital Management LLC grew its stake in MediWound by 7.8% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 85,184 shares of the biopharmaceutical company’s stock worth $1,214,000 after buying an additional 6,200 shares in the last quarter. Hedge funds and other institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.